A drug that cools the body’s reaction to Covid-19 appears to save lives

In an advance toward conquering covid-19, doctors in Michigan say an antibody drug may sharply cut the chance patients on a ventilator will die.
The problem: The pandemic viral disease is infecting millions, and for those who end up on a ventilator in an ICU, the odds are grim. More than half are dying.
The drug: Doctors at the University of Michigan set out to control the haywire immune reaction that pushes some covid-19 patients into a death spiral. To do it, they gave 78 patients on ventilators the drug tocilizumab, which blocks IL-6, a molecule in the body that sets off a reaction to an infection. (The drug is sold by Roche under the trade name Actemra.)
The result: The doctors say in a preprint that patients who got the drug were 45% less likely to die than those who didn’t. But there’s a big caveat, which is that the doctors knew which patients got the drug and which didn’t. Their picks for the drug-taking group could have been biased— people more likely to improve anyway, for example—so further studies are needed.
Emerging cocktail: In late May, Roche said it would start a trial to combine its IL-6 blocker with remdesivir, an antiviral drug with modest benefits that got emergency approval in the US for treating covid-19. That drug is meant to block the virus from replicating.
By combining the two drugs, doctors may be closing in on a cocktail able to cut the death rate from the virus, a step that would help society return to normal.
Deep Dive
Biotechnology
These scientists used CRISPR to put an alligator gene into catfish
The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.
Next up for CRISPR: Gene editing for the masses?
Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.
CRISPR for high cholesterol: 10 Breakthrough Technologies 2023
New forms of the gene-editing tool could enable treatments for common diseases.
This biotech startup says mice live longer after genetic reprogramming
The result is a widely anticipated landmark for rejuvenation technology.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.